VYMI240816C66000
- 4.90
- 0.000.00%
Vanguard International High Dividend Yield Etf Newsroom
Everything You Need to Know on Thursday: RBC Restructures, Divides Key Banking Division into Two
Good morning mooers! Here are things you need to know about today's market:
TD, Royal Bank of Canada Mute Declines in Barrick, Newmont, Sending TSX Higher
Canadian stocks gained Monday as the rally in banks offset the declines in energy and metals and mining.
Reported Thursday, Roche's Genentech Halts SKYSCRAPER-06 Trial After Tiragolumab Plus Tecentriq And Chemotherapy Show Reduced Efficacy Compared To Comparator Arm
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim analysis
Roche's Genentech Receives FDA Approval For Vabysmo Prefilled Syringe (PFS) To Treat Three Leading Causes Of Vision Loss
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness –Designed to simplify administration, Vabysmo PFS prov
2024 Half-Year Recap | 10 Dividend-Monster Stocks in Canadian Market
Earlier today, Statistics Canada issued May inflation report, indicating that Canada's annual rate of inflation unexpectedly rose 2.9% in May, surpassing the expected 2.7%. This development might unsettle the market's anticipation of a rate cut coming in July. Nonetheless, the data aligns with the Bank of Canada's target range for inflation control, set at 1%-3%. Before the report's release, market consensus had been that the Ba...
Western Bank Surges 60% After 100% Premium Acquisition: Who Could Be the Next Buying Target?
National Bank has agreed to purchase
Roche's VENTANA DP 200 Digital System Approved For Diagnostic Use By FDA
The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling pathologists to diagnose
Reported Saturday, Genentech's Phase III STARGLO Study Shows Columvi Increases Survival For Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columv
Canadian Rate Cut Winners: BNS Leads the Banking Sector with Top Dividend Yield
Stay Connected.Stay Informed. Follow me on MooMoo!
Canadian Rate Cut Winners: RBC，A Golden Choice in the Tide of Rate Reductions
Stay Connected.Stay Informed. Follow me on MooMoo!
Scotiabank Maintains Sector Outperform on Royal Bank of Canada, Raises Price Target to C$157
Scotiabank analyst Meny Grauman maintains Royal Bank of Canada (TSX:RY) with a Sector Outperform and raises the price target from C$153 to C$157.
Big Five Banks' Earnings Unveiled. Which Bank Stock Should be the Top Pick?
Canada's most prominent banks have just closed the books on their second-quarter earnings. Amidst concerns about high borrowing costs and a slowdown in economic growth, the Big Five—
Unlocking Potential Opportunities Following Canada's Interest Rate Cut: An Investment Guide for High Dividend ETFs
In the previous article introducing REITs, we analyzed the interest rate reduction expectations in Canada and recommended a series of REITs and related ETFs as good investment targets in the event of lower interest rates：
Canadian Stock Series: RBC—A Combination of Growth and High Dividends
(RBC) released its financial report for the second quarter of the 2024 fiscal year on May 30th, 2024, Eastern Time. Driven by the growth in banking and capital market business revenue, the company's overall performance was commendable.
Earnings Call Summary | Royal Bank of Canada(RY.US) Q2 2024 Earnings Conference
The following is a summary of the Royal Bank of Canada (RY) Q2 2024 Earnings Call Transcript:Financial Performance:Royal Bank of Canada reported Q2 earnings of $4 billion, with adjusted earnings reach
Everything You Need to Know on Thursday: Financial Stocks Gain Pre-Bell Thursday
Good morning mooers! Here are things you need to know about today's market:
Roche's Genentech Granted Priority Review By FDA For Inavolisib, An Investigational Oral Therapy, In Combination With Palbociclib (Ibrance) And Fulvestrant
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options –– Additional analyses of INAVO120 will be presented in an
Reported Earlier, Roche And Hitachi High-Tech Extend 46-Year Partnership For Diagnostic Testing Advances
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for customers and patients worldwideUpcoming launches of t
RBC, TD, Scotiabank, BMO, CIBC Earnings Preview: Will Continued High Interest Rates Hit Canada's Banks?
Canada's major banks are about to announce their Q2 financial quarter results. Sustained high interest rates pose challenges to residents' repayment ability. Banks' real estate exposure and credit card risks are the focus of investors' attention. Meanwhile, the recovery in the capital market means that banks' fee income may rebound.
Everything You Need to Know on Tuesday: RBC Poised to Outperform Rivals Due to HSBC Acquisition, Say Analysts
Good morning mooers! Here are things you need to know about today's market: